|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PRLR |
Gene summary for PRLR |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PRLR | Gene ID | 5618 |
| Gene name | prolactin receptor | |
| Gene Alias | HPRL | |
| Cytomap | 5p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P16471 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5618 | PRLR | GSM4909293 | Human | Breast | IDC | 9.59e-11 | 3.20e-01 | 0.1581 |
| 5618 | PRLR | GSM4909298 | Human | Breast | IDC | 3.79e-14 | 4.59e-01 | 0.1551 |
| 5618 | PRLR | GSM4909302 | Human | Breast | IDC | 1.52e-13 | 5.00e-01 | 0.1545 |
| 5618 | PRLR | GSM4909303 | Human | Breast | IDC | 4.67e-08 | 5.72e-01 | 0.0438 |
| 5618 | PRLR | GSM4909306 | Human | Breast | IDC | 5.45e-07 | 3.52e-01 | 0.1564 |
| 5618 | PRLR | GSM4909311 | Human | Breast | IDC | 4.79e-09 | -1.18e-01 | 0.1534 |
| 5618 | PRLR | GSM4909317 | Human | Breast | IDC | 1.68e-12 | 3.93e-01 | 0.1355 |
| 5618 | PRLR | GSM4909319 | Human | Breast | IDC | 4.39e-12 | -1.32e-01 | 0.1563 |
| 5618 | PRLR | GSM4909321 | Human | Breast | IDC | 3.34e-04 | -1.21e-01 | 0.1559 |
| 5618 | PRLR | M1 | Human | Breast | IDC | 4.18e-05 | 3.20e-01 | 0.1577 |
| 5618 | PRLR | NCCBC2 | Human | Breast | DCIS | 2.96e-03 | 4.80e-01 | 0.1554 |
| 5618 | PRLR | P1 | Human | Breast | IDC | 2.02e-03 | 1.23e-01 | 0.1527 |
| 5618 | PRLR | P3 | Human | Breast | IDC | 2.26e-03 | 5.24e-01 | 0.1542 |
| 5618 | PRLR | DCIS2 | Human | Breast | DCIS | 1.06e-25 | -4.69e-02 | 0.0085 |
| 5618 | PRLR | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.82e-09 | -3.84e-01 | 0.0155 |
| 5618 | PRLR | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.54e-02 | -4.76e-01 | -0.1207 |
| 5618 | PRLR | HTA11_696_2000001011 | Human | Colorectum | AD | 3.79e-02 | -2.72e-01 | -0.1464 |
| 5618 | PRLR | HTA11_866_2000001011 | Human | Colorectum | AD | 7.05e-03 | -3.08e-01 | -0.1001 |
| 5618 | PRLR | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.37e-02 | -4.09e-01 | 0.0338 |
| 5618 | PRLR | HTA11_99999970781_79442 | Human | Colorectum | MSS | 5.98e-09 | -3.87e-01 | 0.294 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000756511 | Breast | IDC | female pregnancy | 39/1434 | 193/18723 | 1.81e-08 | 1.27e-06 | 39 |
| GO:00447061 | Breast | IDC | multi-multicellular organism process | 41/1434 | 220/18723 | 8.58e-08 | 5.19e-06 | 41 |
| GO:004873214 | Breast | IDC | gland development | 64/1434 | 436/18723 | 3.47e-07 | 1.74e-05 | 64 |
| GO:000756611 | Breast | IDC | embryo implantation | 14/1434 | 53/18723 | 3.14e-05 | 7.32e-04 | 14 |
| GO:005087813 | Breast | IDC | regulation of body fluid levels | 50/1434 | 379/18723 | 1.12e-04 | 2.10e-03 | 50 |
| GO:003087911 | Breast | IDC | mammary gland development | 23/1434 | 137/18723 | 2.87e-04 | 4.37e-03 | 23 |
| GO:00066944 | Breast | IDC | steroid biosynthetic process | 25/1434 | 173/18723 | 1.56e-03 | 1.56e-02 | 25 |
| GO:00075652 | Breast | DCIS | female pregnancy | 37/1390 | 193/18723 | 7.85e-08 | 4.47e-06 | 37 |
| GO:00447062 | Breast | DCIS | multi-multicellular organism process | 39/1390 | 220/18723 | 3.05e-07 | 1.46e-05 | 39 |
| GO:004873223 | Breast | DCIS | gland development | 60/1390 | 436/18723 | 2.50e-06 | 8.74e-05 | 60 |
| GO:005087823 | Breast | DCIS | regulation of body fluid levels | 50/1390 | 379/18723 | 5.17e-05 | 1.06e-03 | 50 |
| GO:00075662 | Breast | DCIS | embryo implantation | 13/1390 | 53/18723 | 1.00e-04 | 1.82e-03 | 13 |
| GO:003087921 | Breast | DCIS | mammary gland development | 22/1390 | 137/18723 | 4.74e-04 | 6.24e-03 | 22 |
| GO:000669411 | Breast | DCIS | steroid biosynthetic process | 23/1390 | 173/18723 | 4.63e-03 | 3.52e-02 | 23 |
| GO:00075952 | Breast | DCIS | lactation | 9/1390 | 47/18723 | 6.96e-03 | 4.78e-02 | 9 |
| GO:0048732 | Colorectum | AD | gland development | 149/3918 | 436/18723 | 6.07e-11 | 6.33e-09 | 149 |
| GO:0030879 | Colorectum | AD | mammary gland development | 53/3918 | 137/18723 | 1.46e-06 | 4.58e-05 | 53 |
| GO:0009755 | Colorectum | AD | hormone-mediated signaling pathway | 64/3918 | 190/18723 | 2.78e-05 | 5.24e-04 | 64 |
| GO:0033674 | Colorectum | AD | positive regulation of kinase activity | 131/3918 | 467/18723 | 1.28e-04 | 1.85e-03 | 131 |
| GO:0050878 | Colorectum | AD | regulation of body fluid levels | 108/3918 | 379/18723 | 2.54e-04 | 3.20e-03 | 108 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04151 | Colorectum | FAP | PI3K-Akt signaling pathway | 75/1404 | 354/8465 | 1.23e-02 | 4.19e-02 | 2.55e-02 | 75 |
| hsa041511 | Colorectum | FAP | PI3K-Akt signaling pathway | 75/1404 | 354/8465 | 1.23e-02 | 4.19e-02 | 2.55e-02 | 75 |
| hsa041512 | Colorectum | CRC | PI3K-Akt signaling pathway | 64/1091 | 354/8465 | 2.70e-03 | 1.77e-02 | 1.20e-02 | 64 |
| hsa041513 | Colorectum | CRC | PI3K-Akt signaling pathway | 64/1091 | 354/8465 | 2.70e-03 | 1.77e-02 | 1.20e-02 | 64 |
| hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
| hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
| hsa04917 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
| hsa049171 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PRLR | SNV | Missense_Mutation | c.199G>A | p.Glu67Lys | p.E67K | P16471 | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| PRLR | SNV | Missense_Mutation | rs764438076 | c.253N>C | p.Ser85Pro | p.S85P | P16471 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-BH-A1FH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| PRLR | SNV | Missense_Mutation | c.1465N>A | p.Asp489Asn | p.D489N | P16471 | protein_coding | tolerated(0.11) | benign(0.012) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| PRLR | SNV | Missense_Mutation | rs764438076 | c.253N>C | p.Ser85Pro | p.S85P | P16471 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-E2-A1L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| PRLR | SNV | Missense_Mutation | rs764438076 | c.253T>C | p.Ser85Pro | p.S85P | P16471 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-E9-A1RE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
| PRLR | SNV | Missense_Mutation | rs754093703 | c.251A>C | p.Asn84Thr | p.N84T | P16471 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-EW-A1PH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| PRLR | deletion | Frame_Shift_Del | c.466delC | p.Leu156Ter | p.L156* | P16471 | protein_coding | TCGA-A2-A25D-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |||
| PRLR | insertion | Nonsense_Mutation | novel | c.1285_1286insAGC | p.Ser429delinsTer | p.S429delins* | P16471 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| PRLR | insertion | Frame_Shift_Ins | novel | c.1284_1285insCGCATGTTTTACACACTCCTTTCACTGA | p.Ser429ArgfsTer16 | p.S429Rfs*16 | P16471 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| PRLR | deletion | Frame_Shift_Del | novel | c.1079delN | p.Leu360CysfsTer38 | p.L360Cfs*38 | P16471 | protein_coding | TCGA-AC-A3EH-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5618 | PRLR | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, KINASE | LFA-102 | |||
| 5618 | PRLR | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, KINASE | SOMATROPIN | SOMATROPIN | ||
| 5618 | PRLR | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, KINASE | DHT | ANDROSTANOLONE | 1544711 | |
| 5618 | PRLR | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, KINASE | SOMATROPIN RECOMBINANT | |||
| 5618 | PRLR | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, KINASE | agonist | 178101594 | ||
| 5618 | PRLR | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, KINASE | Prolanta | |||
| 5618 | PRLR | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, KINASE | Endostatin | ENDOSTATIN | ||
| 5618 | PRLR | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, KINASE | agonist | 178101593 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |